Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer.

PubWeight™: 2.54‹?› | Rank: Top 2%

🔗 View Article (PMID 18791714)

Published in Cancer Immunol Immunother on September 13, 2008

Authors

Ninke Leffers1, Marloes J M Gooden, Renske A de Jong, Baukje-Nynke Hoogeboom, Klaske A ten Hoor, Harry Hollema, H Marieke Boezen, Ate G J van der Zee, Toos Daemen, Hans W Nijman

Author Affiliations

1: Department of Gynecological Oncology, University Medical Center Groningen, University of Groningen,Groningen, The Netherlands. n.leffers@og.umcg.nl

Associated clinical trials:

Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC | NCT02591615

Articles citing this

The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer (2012) 10.90

Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer (2012) 5.15

The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer (2011) 3.45

Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol Oncol (2011) 2.67

T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res (2012) 2.43

Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS One (2009) 2.36

Trial watch: Prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology (2012) 1.78

Digital genomic quantification of tumor-infiltrating lymphocytes. Sci Transl Med (2013) 1.72

An immunologic portrait of cancer. J Transl Med (2011) 1.50

Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research. Front Oncol (2013) 1.29

Different subsets of tumor infiltrating lymphocytes correlate with NPC progression in different ways. Mol Cancer (2010) 1.28

Intraepithelial CD8-positive T lymphocytes predict survival for patients with serous stage III ovarian carcinomas: relevance of clonal selection of T lymphocytes. Br J Cancer (2009) 1.25

HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8⁺ T lymphocytes. Proc Natl Acad Sci U S A (2011) 1.17

Absolute lymphocyte count is associated with survival in ovarian cancer independent of tumor-infiltrating lymphocytes. J Transl Med (2012) 1.16

Tumor-infiltrating regulatory T cells: phenotype, role, mechanism of expansion in situ and clinical significance. Cancer Microenviron (2012) 1.15

The accumulation and prognosis value of tumor infiltrating IL-17 producing cells in esophageal squamous cell carcinoma. PLoS One (2011) 1.15

A reversed CD4/CD8 ratio of tumor-infiltrating lymphocytes and a high percentage of CD4(+)FOXP3(+) regulatory T cells are significantly associated with clinical outcome in squamous cell carcinoma of the cervix. Cell Mol Immunol (2010) 1.13

Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. J Hematol Oncol (2016) 1.12

Tumor-host interactions: the role of inflammation. Histochem Cell Biol (2008) 1.11

The prognostic impact of anti-cancer immune response: a novel classification of cancer patients. Semin Immunopathol (2011) 1.09

Prognostic value of tumor-infiltrating FoxP3(+) regulatory T cells in cancers: a systematic review and meta-analysis. Sci Rep (2015) 1.07

Immunity and immune suppression in human ovarian cancer. Immunotherapy (2011) 1.07

IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo. Oncoimmunology (2015) 1.04

Signals through 4-1BB inhibit T regulatory cells by blocking IL-9 production enhancing antitumor responses. Cancer Immunol Immunother (2011) 1.03

Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen. Clin Cancer Res (2010) 1.02

Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer. J Transl Med (2013) 1.01

Multifaceted therapeutic targeting of ovarian peritoneal carcinomatosis through virus-induced immunomodulation. Mol Ther (2012) 0.99

The immune microenvironment of human tumors: general significance and clinical impact. Cancer Microenviron (2012) 0.98

Contribution of the immune system to the chemotherapeutic response. Semin Immunopathol (2011) 0.98

Overexpression of CD73 in epithelial ovarian carcinoma is associated with better prognosis, lower stage, better differentiation and lower regulatory T cell infiltration. J Gynecol Oncol (2012) 0.97

Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer. Ann Oncol (2013) 0.96

Gut microbiota and the paradox of cancer immunotherapy. Front Immunol (2014) 0.95

Identification of genes and pathways associated with cytotoxic T lymphocyte infiltration of serous ovarian cancer. Br J Cancer (2010) 0.95

Intraepithelial T cells and tumor-associated macrophages in ovarian cancer patients. Cancer Immun (2013) 0.94

The role of regulatory T cells in cancer. Immune Netw (2009) 0.93

Randomized controlled trial to evaluate the effects of progressive resistance training compared to progressive muscle relaxation in breast cancer patients undergoing adjuvant radiotherapy: the BEST study. BMC Cancer (2013) 0.91

Epithelial cell-adhesion molecule-directed trifunctional antibody immunotherapy for symptom management of advanced ovarian cancer. Clin Pharmacol (2013) 0.91

Prognostic biomarkers in endometrial and ovarian carcinoma. Virchows Arch (2014) 0.90

Fabrication and functional characterization of goldnanoconjugates for potential application in ovarian cancer. J Mater Chem (2010) 0.90

A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer. J Transl Med (2015) 0.89

Markers of T cell infiltration and function associate with favorable outcome in vascularized high-grade serous ovarian carcinoma. PLoS One (2013) 0.89

IRF-1 responsiveness to IFN-γ predicts different cancer immune phenotypes. Br J Cancer (2013) 0.89

Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients--a study of the OVCAD consortium. BMC Cancer (2013) 0.89

Prognostic significance of B-cells and pSTAT3 in patients with ovarian cancer. PLoS One (2013) 0.89

B7-H1 limits the entry of effector CD8(+) T cells to the memory pool by upregulating Bim. Oncoimmunology (2012) 0.88

The immune cell infiltrate populating meningiomas is composed of mature, antigen-experienced T and B cells. Neuro Oncol (2013) 0.87

FOXP3 gene polymorphism is associated with hepatitis B-related hepatocellular carcinoma in China. J Exp Clin Cancer Res (2013) 0.86

A review of the application of inflammatory biomarkers in epidemiologic cancer research. Cancer Epidemiol Biomarkers Prev (2014) 0.86

The immune system in the pathogenesis of ovarian cancer. Crit Rev Immunol (2013) 0.86

Decreased ratio of CD8+ T cells to regulatory T cells associated with decreased survival in dogs with osteosarcoma. J Vet Intern Med (2010) 0.86

CD4+CD25hiCD127low regulatory T cells are increased in oral squamous cell carcinoma patients. PLoS One (2014) 0.86

Tumor infiltrating lymphocytes in ovarian cancer. Cancer Biol Ther (2015) 0.85

Elevated serum CXCL16 is an independent predictor of poor survival in ovarian cancer and may reflect pro-metastatic ADAM protease activity. Br J Cancer (2014) 0.84

Prognostic impact of peritumoral lymphocyte infiltration in soft tissue sarcomas. BMC Clin Pathol (2012) 0.84

Retracted Targeted immune therapy of ovarian cancer. Cancer Metastasis Rev (2015) 0.84

VEGF Potentiates GD3-Mediated Immunosuppression by Human Ovarian Cancer Cells. Clin Cancer Res (2016) 0.84

Predicting success or failure of immunotherapy for cancer: insights from a clinically applicable mathematical model. Am J Cancer Res (2012) 0.83

Predictive and prognostic protein biomarkers in epithelial ovarian cancer: recommendation for future studies. Cancers (Basel) (2010) 0.83

Comparative study of various subpopulations of cytotoxic cells in blood and ascites from patients with ovarian carcinoma. Contemp Oncol (Pozn) (2015) 0.83

Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting. Vaccines (Basel) (2016) 0.82

Characterization of the inflammatory response to solid cancer metastases in the human brain. Clin Exp Metastasis (2012) 0.82

Urokinase-type plasminogen activator deficiency promotes neoplasmatogenesis in the colon of mice. Transl Oncol (2014) 0.82

Depletion of regulatory T lymphocytes reverses the imbalance between pro- and anti-tumor immunities via enhancing antigen-specific T cell immune responses. PLoS One (2012) 0.82

The prognostic effects of tumor infiltrating regulatory T cells and myeloid derived suppressor cells assessed by multicolor flow cytometry in gastric cancer patients. Oncotarget (2016) 0.81

Epithelial ovarian cancer - more data, more questions? Wien Med Wochenschr (2014) 0.80

Mitotic count reflects prognosis of gallbladder cancer particularly among patients with T3 tumor. Mol Clin Oncol (2013) 0.80

CD45RO(+) Memory T Lymphocytes - a Candidate Marker for TNM-Immunoscore in Squamous Non-Small Cell Lung Cancer. Neoplasia (2015) 0.80

Macrophage-derived chemokine CCL22 and regulatory T cells in ovarian cancer patients. Tumour Biol (2015) 0.79

Molecular profiling and clinical outcome of high-grade serous ovarian cancer presenting with low- versus high-volume ascites. Biomed Res Int (2014) 0.79

Tumor-infiltrating memory T-lymphocytes for prognostic prediction in cancer patients: a meta-analysis. Int J Clin Exp Med (2015) 0.79

Infiltration of dendritic cells and T lymphocytes predicts favorable outcome in epithelial ovarian cancer. Cancer Gene Ther (2015) 0.78

Infiltrating CTLs are bothered by HLA-E on tumors. Oncoimmunology (2012) 0.78

Effects of radiation on T regulatory cells in normal states and cancer: mechanisms and clinical implications. Am J Cancer Res (2015) 0.78

Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2? Semin Immunol (2016) 0.78

CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCRαβ+ CD8αβ+ T cells that can be targeted for cancer immunotherapy. Oncotarget (2016) 0.78

Size matters: Survival benefit conferred by intratumoral T cells is dependent on surgical outcome, treatment sequence and T cell differentiation. Oncoimmunology (2016) 0.77

The diverse roles of the TNF axis in cancer progression and metastasis. Trends Cancer Res (2016) 0.77

Interleukin-6 receptor and its ligand interleukin-6 are opposite markers for survival and infiltration with mature myeloid cells in ovarian cancer. Oncoimmunology (2015) 0.77

Anti-ovarian tumor response of donor peripheral blood mononuclear cells is due to infiltrating cytotoxic NK cells. Oncotarget (2016) 0.77

CD20(+) T cells have a predominantly Tc1 effector memory phenotype and are expanded in the ascites of patients with ovarian cancer. Oncoimmunology (2015) 0.76

Increased frequency of CD4+ CD25+ FOXP3+ cells correlates with the progression of 4-nitroquinoline1-oxide-induced rat tongue carcinogenesis. Clin Oral Investig (2013) 0.76

Immune cells in the normal ovary and spontaneous ovarian tumors in the laying hen (Gallus domesticus) model of human ovarian cancer. PLoS One (2013) 0.76

Deconvolution of the gene expression profiles of valuable banked blood specimens for studying the prognostic values of altered peripheral immune cell proportions in cancer patients. PLoS One (2014) 0.76

Rab25 Small GTPase Mediates Secretion of Tumor Necrosis Factor Receptor Superfamily Member 11b (osteoprotegerin) Protecting Cancer Cells from Effects of TRAIL. J Genet Syndr Gene Ther (2013) 0.75

Prediction model for regional or distant recurrence in endometrial cancer based on classical pathological and immunological parameters. Br J Cancer (2015) 0.75

Inverse correlation between CD8(+) inflammatory cells and E-cadherin expression in gallbladder cancer: Tissue microarray and imaging analysis. World J Clin Cases (2017) 0.75

Differential distribution of tumor-associated macrophages and Treg/Th17 cells in the progression of malignant and benign epithelial ovarian tumors. Oncol Lett (2016) 0.75

Antigen processing and immune regulation in the response to tumours. Immunology (2016) 0.75

The Prognostic Value of Baseline Lymphocyte, Neutrophil, and Monocyte Counts in Locally Advanced Cervical Carcinoma Treated with Radiation. Obstet Gynecol Int (2017) 0.75

Crucial Contributions by T Lymphocytes (Effector, Regulatory, and Checkpoint Inhibitor) and Cytokines (TH1, TH2, and TH17) to a Pathological Complete Response Induced by Neoadjuvant Chemotherapy in Women with Breast Cancer. J Immunol Res (2016) 0.75

Therapeutic targets and new directions for antibodies developed for ovarian cancer. MAbs (2016) 0.75

The prognostic value of tumor-infiltrating T lymphocytes in ovarian cancer. Oncotarget (2017) 0.75

Overexpression of GPC6 and TMEM132D in Early Stage Ovarian Cancer Correlates with CD8+ T-Lymphocyte Infiltration and Increased Patient Survival. Biomed Res Int (2015) 0.75

The Antitumor Efficacy of IL2/IL21-Cultured Polyfunctional Neu-Specific T Cells Is TNFα/IL17 Dependent. Clin Cancer Res (2015) 0.75

FOXP3 Allelic Variants and Haplotype Structures Are Associated with Aggressive Breast Cancer Subtypes. Dis Markers (2017) 0.75

Association between tumour infiltrating lymphocytes, histotype and clinical outcome in epithelial ovarian cancer. BMC Cancer (2017) 0.75

Clinical and biological effects of tumor-associated lymphocytes in the presence or absence of chemotherapy for malignant ascites in ovarian cancer patients. Oncol Lett (2017) 0.75

Systemic inflammation is associated with the density of immune cells in the tumor microenvironment of gastric cancer. Gastric Cancer (2016) 0.75

Articles by these authors

Evidence based selection of housekeeping genes. PLoS One (2007) 7.90

Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results. Nat Med (2011) 7.82

Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res (2004) 5.68

Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. J Clin Oncol (2004) 2.32

Molecular and clinical characteristics of MSH6 variants: an analysis of 25 index carriers of a germline variant. Am J Hum Genet (2002) 2.17

Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma. Cancer Res (2010) 2.03

Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients. J Clin Oncol (2005) 2.01

Survival-related profile, pathways, and transcription factors in ovarian cancer. PLoS Med (2009) 1.88

Size of sentinel-node metastasis and chances of non-sentinel-node involvement and survival in early stage vulvar cancer: results from GROINSS-V, a multicentre observational study. Lancet Oncol (2010) 1.84

In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med (2007) 1.79

Genome-wide promoter analysis uncovers portions of the cancer methylome. Cancer Res (2008) 1.70

Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinoma. BMC Cancer (2009) 1.70

Intraoperative near-infrared fluorescence tumor imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting antibodies. J Nucl Med (2011) 1.62

Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group. Clin Cancer Res (2007) 1.60

Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma. Cancer (2006) 1.55

Management of extracolonic tumours in patients with Lynch syndrome. Lancet Oncol (2009) 1.53

Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial. J Clin Oncol (2009) 1.44

Germline hypermethylation of MLH1 and EPCAM deletions are a frequent cause of Lynch syndrome. Genes Chromosomes Cancer (2009) 1.43

Intraoperative multispectral fluorescence imaging for the detection of the sentinel lymph node in cervical cancer: a novel concept. Mol Imaging Biol (2011) 1.41

Gynecologic screening in hereditary nonpolyposis colorectal cancer. Gynecol Oncol (2003) 1.36

Toward new strategies to select young endometrial cancer patients for mismatch repair gene mutation analysis. J Clin Oncol (2003) 1.31

VEGF-PET imaging is a noninvasive biomarker showing differential changes in the tumor during sunitinib treatment. Cancer Res (2010) 1.27

Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer. Clin Cancer Res (2009) 1.27

Tissue distribution of the death ligand TRAIL and its receptors. J Histochem Cytochem (2004) 1.27

Serum cytokine profiling as a diagnostic and prognostic tool in ovarian cancer: a potential role for interleukin 7. Clin Cancer Res (2007) 1.27

TP53 codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studies. Lancet Oncol (2009) 1.26

Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial. Int J Cancer (2009) 1.26

Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer. Gynecol Oncol (2007) 1.26

Ras/ERK1/2-mediated STAT3 Ser727 phosphorylation by familial medullary thyroid carcinoma-associated RET mutants induces full activation of STAT3 and is required for c-fos promoter activation, cell mitogenicity, and transformation. J Biol Chem (2007) 1.24

Lymphvascular space involvement: an independent prognostic factor in endometrial cancer. Gynecol Oncol (2005) 1.24

89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922. J Nucl Med (2010) 1.23

Assessment of gene promoter hypermethylation for detection of cervical neoplasia. Int J Cancer (2006) 1.23

Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer. Gynecol Oncol (2008) 1.19

Expression of TRAIL (TNF-related apoptosis-inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas. J Pathol (2003) 1.17

The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis. Cancer Res (2003) 1.15

An oncological view on the blood-testis barrier. Lancet Oncol (2002) 1.15

Five-year quality of life of endometrial cancer patients treated in the randomised Post Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data. Eur J Cancer (2011) 1.14

Improving coeliac disease risk prediction by testing non-HLA variants additional to HLA variants. Gut (2013) 1.14

Involvement of the TGF-beta and beta-catenin pathways in pelvic lymph node metastasis in early-stage cervical cancer. Clin Cancer Res (2011) 1.13

Vulvar carcinoma. The price of less radical surgery. Cancer (2002) 1.12

The effect of chemotherapy on expression of folate receptor-alpha in ovarian cancer. Cell Oncol (Dordr) (2011) 1.10

Profiling studies in ovarian cancer: a review. Oncologist (2007) 1.09

Proteasome inhibitor MG132 sensitizes HPV-positive human cervical cancer cells to rhTRAIL-induced apoptosis. Int J Cancer (2006) 1.08

Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients. J Clin Oncol (2006) 1.08

The virosome concept for influenza vaccines. Vaccine (2005) 1.07

PMS2 involvement in patients suspected of Lynch syndrome. Genes Chromosomes Cancer (2009) 1.07

Support of the 'fallopian tube hypothesis' in a prospective series of risk-reducing salpingo-oophorectomy specimens. Eur J Cancer (2012) 1.07

Targeted exome sequencing in clear cell renal cell carcinoma tumors suggests aberrant chromatin regulation as a crucial step in ccRCC development. Hum Mutat (2012) 1.06

CADM1 and MAL promoter methylation levels in hrHPV-positive cervical scrapes increase proportional to degree and duration of underlying cervical disease. Int J Cancer (2013) 1.06

Detecting cervical cancer by quantitative promoter hypermethylation assay on cervical scrapings: a feasibility study. Mol Cancer Res (2004) 1.04

Expression of epidermal growth factor receptor (EGFR) and activated EGFR predict poor response to (chemo)radiation and survival in cervical cancer. Clin Cancer Res (2009) 1.03

Recombinant alphaviruses as vectors for anti-tumour and anti-microbial immunotherapy. J Clin Virol (2006) 1.02

Molecular markers and clinical behavior of uterine carcinosarcomas: focus on the epithelial tumor component. Mod Pathol (2011) 1.01

The extrinsic apoptosis pathway and its prognostic impact in ovarian cancer. Gynecol Oncol (2009) 1.00

Survival of ovarian cancer patients overexpressing the tumour antigen p53 is diminished in case of MHC class I down-regulation. Gynecol Oncol (2008) 1.00

Methylation markers for CCNA1 and C13ORF18 are strongly associated with high-grade cervical intraepithelial neoplasia and cervical cancer in cervical scrapings. Cancer Epidemiol Biomarkers Prev (2009) 0.99

Enhanced antitumor efficacy of a DR5-specific TRAIL variant over recombinant human TRAIL in a bioluminescent ovarian cancer xenograft model. Clin Cancer Res (2009) 0.99

Genome-wide methylation profiling identifies hypermethylated biomarkers in high-grade cervical intraepithelial neoplasia. Epigenetics (2012) 0.98

Sulindac inhibits beta-catenin expression in normal-appearing colon of hereditary nonpolyposis colorectal cancer and familial adenomatous polyposis patients. Cancer Epidemiol Biomarkers Prev (2005) 0.97

Measurement of tumor VEGF-A levels with 89Zr-bevacizumab PET as an early biomarker for the antiangiogenic effect of everolimus treatment in an ovarian cancer xenograft model. Clin Cancer Res (2012) 0.96

The prognostic role of classical and nonclassical MHC class I expression in endometrial cancer. Int J Cancer (2010) 0.95

TRAIL-receptor expression is an independent prognostic factor for survival in patients with a primary glioblastoma multiforme. J Neurooncol (2006) 0.95

Gene promoter methylation patterns throughout the process of cervical carcinogenesis. Cell Oncol (2010) 0.95

Expression of tumour necrosis factor-related apoptosis-inducing ligand death receptors in sporadic and hereditary colorectal tumours: potential targets for apoptosis induction. Eur J Cancer (2005) 0.95

Endometrial cancer survival after breast cancer in relation to tamoxifen treatment: pooled results from three countries. Breast Cancer Res (2012) 0.94

Distinct regulation and impact of type 1 T-cell immunity against HPV16 L1, E2 and E6 antigens during HPV16-induced cervical infection and neoplasia. Int J Cancer (2006) 0.94

Multispectral real-time fluorescence imaging for intraoperative detection of the sentinel lymph node in gynecologic oncology. J Vis Exp (2010) 0.94

Intraoperative imaging in ovarian cancer: fact or fiction? Mol Imaging (2011) 0.94